US equities
|
NVDA
$238.90
▲+2.12%
SPCX
$171.09
▲+7.63%
MU
$1,063.96
▼-1.02%
TSLA
$378.73
▲+2.20%
WBD
$30.95
▲+0.03%
MSFT
$525.18
▲+1.48%
SNDK
$1,704.16
▼-0.92%
AAPL
$332.89
▼-0.24%
NVDA
$238.90
▲+2.12%
SPCX
$171.09
▲+7.63%
MU
$1,063.96
▼-1.02%
TSLA
$378.73
▲+2.20%
WBD
$30.95
▲+0.03%
MSFT
$525.18
▲+1.48%
SNDK
$1,704.16
▼-0.92%
AAPL
$332.89
▼-0.24%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Caribou Biosciences, Inc. - Common Stock
(NQ:
CRBU
)
1.190
-0.030 (-2.46%)
Delayed Quote
Updated: 4:00 PM EDT, Oct 5, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Caribou Biosciences, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Caribou Biosciences to Participate in the Citi 2025 Biopharma Back to School Conference
August 25, 2025
From
Caribou Biosciences, Inc.
Via
GlobeNewswire
Caribou Biosciences Inc (NASDAQ:CRBU) Posts Mixed Q2 2025 Earnings with Revenue Beat but Wider Loss
↗
August 12, 2025
Caribou Biosciences reports Q2 2025 earnings with revenue beating estimates at $2.67M but a wider EPS loss of -$0.58. Clinical updates expected in H2 2025.
Via
Chartmill
Caribou Biosciences Reports Second Quarter 2025 Financial Results and Provides Business Update
August 12, 2025
From
Caribou Biosciences, Inc.
Via
GlobeNewswire
CARIBOU ALERT: Bragar Eagel & Squire, P.C. is Investigating Caribou Biosciences, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
July 25, 2025
From
Bragar Eagel & Squire
Via
GlobeNewswire
FDA Halts Trials Exporting Americans' Cells To Hostile Countries For Genetic Engineering
↗
June 20, 2025
FDA launches review of trials that sent American DNA to China without full consent; NIH investigates impact of Biden-era exemption on federally funded research
Via
Benzinga
Caribou Biosciences to Participate in the Jefferies Global Healthcare Conference
May 28, 2025
From
Caribou Biosciences, Inc.
Via
GlobeNewswire
Caribou Biosciences Reports First Quarter 2025 Financial Results and Provides Business Update
May 08, 2025
From
Caribou Biosciences, Inc.
Via
GlobeNewswire
Caribou Biosciences to Participate in the BofA Securities 2025 Health Care Conference
May 06, 2025
From
Caribou Biosciences, Inc.
Via
GlobeNewswire
Caribou Biosciences Announces Strategic Pipeline Prioritization with Focus on CB-010 and CB-011 Oncology Programs
April 24, 2025
From
Caribou Biosciences, Inc.
Via
GlobeNewswire
Caribou Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
March 10, 2025
From
Caribou Biosciences, Inc.
Via
GlobeNewswire
CARIBOU ALERT: Bragar Eagel & Squire, P.C. is Investigating Caribou Biosciences, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
March 06, 2025
From
Bragar Eagel & Squire
Via
GlobeNewswire
CRBU DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Caribou Biosciences, Inc. Investors to Secure Counsel Before Important February 24 Deadline in Securities Class Action - CRBU
February 19, 2025
From
The Rosen Law Firm PA
Via
GlobeNewswire
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Caribou Biosciences
February 19, 2025
From
Faruqi & Faruqi LLP
Via
GlobeNewswire
Caribou Biosciences to Participate in Upcoming Investor Conferences
February 18, 2025
From
Caribou Biosciences, Inc.
Via
GlobeNewswire
CRBU Deadline: Rosen Law Firm Urges Caribou Biosciences, Inc. (NASDAQ: CRBU) Investors to Contact the Firm for Information About Their Rights
February 15, 2025
From
Rosen Law Firm
Via
Business Wire
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Caribou Biosciences
February 12, 2025
From
Faruqi & Faruqi LLP
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Capri, Caribou, BioAge, and Transocean and Encourages Investors to Contact the Firm
February 10, 2025
From
Bragar Eagel & Squire
Via
GlobeNewswire
ROSEN, A LEADING NATIONAL FIRM, Encourages Caribou Biosciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CRBU
February 07, 2025
From
The Rosen Law Firm PA
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Capri, Caribou, Nextracker, and Transocean and Encourages Investors to Contact the Firm
February 03, 2025
From
Bragar Eagel & Squire
Via
GlobeNewswire
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Caribou Biosciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CRBU
January 31, 2025
From
The Rosen Law Firm PA
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against BioAge, Caribou, FTAI, and Revance and Encourages Investors to Contact the Firm
January 29, 2025
From
Bragar Eagel & Squire
Via
GlobeNewswire
DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Caribou Biosciences
January 29, 2025
From
Faruqi & Faruqi LLP
Via
GlobeNewswire
TOP RANKED ROSEN LAW FIRM Encourages Caribou Biosciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CRBU
January 25, 2025
From
The Rosen Law Firm PA
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Capri, Caribou, Nextracker, and Transocean and Encourages Investors to Contact the Firm
January 22, 2025
From
Bragar Eagel & Squire
Via
GlobeNewswire
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Caribou Biosciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CRBU
January 22, 2025
From
The Rosen Law Firm PA
Via
GlobeNewswire
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Caribou Biosciences
January 22, 2025
From
Faruqi & Faruqi LLP
Via
GlobeNewswire
ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Caribou Biosciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CRBU
January 19, 2025
From
The Rosen Law Firm PA
Via
GlobeNewswire
Faruqi & Faruqi Reminds Caribou Biosciences Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 24, 2025 - CRBU
January 17, 2025
From
Faruqi & Faruqi LLP
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Capri, Caribou, BioAge, and Transocean and Encourages Investors to Contact the Firm
January 14, 2025
From
Bragar Eagel & Squire
Via
GlobeNewswire
Caribou Biosciences, Inc. Shareholders are Encouraged to Contact Robbins LLP for Information About the Lead Plaintiff Deadline in the CRBU Class Action
January 13, 2025
From
Robbins LLP
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
